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Upper and Lower Gastrointestinal Endoscopic Findings
in HIV-Infected Patients in the Era of Highly Active
Antiretroviral Therapy
Russell Parvina, Sindhura Kollia, c, Jamil Shaha, Manan Jhaverib,
Madhavi Reddya

Abstract
Background: Endoscopic evaluation with biopsies are instrumental
in the diagnosis and management of gastrointestinal (GI) disorders
in the setting of human immunodeficiency virus (HIV) or acquired
immunodeficiency syndrome (AIDS), especially in the era of highly
active antiretroviral therapy (HAART).
Methods: A retrospective chart review of 304 HIV-positive and 199
HIV-negative patients who had undergone upper and/or lower endoscopy in an urban community hospital from the years 2012 - 2017 was
performed. Inclusion criteria included men and women between the
ages of 45 to 75 years, which had undergone colonoscopies between
within 2012 - 2017 and had tested positive for HIV. They were selected from that population if they had complete charts that included information regarding symptoms, viral load, cluster of differentiation 4
(CD4) count, prescribed HAART medication, findings from the upper
and lower colonoscopy both from the gastroenterologist’s report and
pathologist’s report. Only then would they be added to the pool of final selection that we could compute data from and draw conclusions.
Results: Among HIV patients, those with less than 200 CD4 cells/
µL counts had lower rates of diverticulosis and hemorrhoids, as compared with those with greater than 200 cells/µL counts. Other gross
and histological findings (from either upper or lower endoscopy) were
not statistically different between these two groups. In HIV-positive
patients, gastritis, Helicobacter pylori (HP) infection, and esophagitis
were significantly less common, while Candida esophagitis was more
common. Among HIV patients taking different HAART regimens, the
prevalence of peptic ulcers was significantly higher in those taking IIs
than that in those who were not.
Conclusions: Physicians should consider the possibility that the GI
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symptoms in HIV-infected patients on HAART may be due to an
opportunistic infection, even when the CD4 count is more than 200
cells/µL and the viral load is low.
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Introduction
Gastrointestinal (GI) symptoms and pathology are very common in patients infected with human immunodeficiency virus
(HIV), affecting almost half of this population [1]. GI disorders
and their presentations in setting of HIV or acquired immunodeficiency syndrome (AIDS) are varied and often nonspecific,
and endoscopic evaluation with biopsies are instrumental in
their diagnosis and management. Possible etiologies of GI
complaints in HIV disease may include the HIV itself, opportunistic and non-opportunistic infections, side-effects of medications, and disease processes unrelated to HIV. The prevalence and incidence of many GI disorders in HIV have changed
dramatically in the era of highly active antiretroviral therapy
(HAART), particularly with the newer generation of HIV regimens. In this retrospective chart review, we report upper and
lower GI endoscopic findings in HIV-infected patients in an
urban, community hospital. We have also examined patterns
of GI findings in patients with low versus high CD4 counts, as
well as those taking various regimens of HAART.

Materials and Methods
We performed a retrospective chart review of 304 HIV-positive and 199 HIV-negative patients who had undergone upper
and/or lower endoscopy at our hospital over the past 5 years
(2012 -2017). The patients included for data collection and
analysis were randomly selected from a larger pool of patients
who had met inclusion criteria. Inclusion criteria were all nonpregnant adult patients who had undergone endoscopy at our
hospital. The study sample was divided into HIV-positive and
HIV-negative patients. The HIV-positive group was further divided into several categories, including those with CD4 counts
below 200 cells/µL versus those with CD4 counts of 200 cells/
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Table 1. Endoscopy Indications, Gross Findings, and Histological Findings
HIV-negative (n = 199)

HIV-positive (n = 304)

P value

   Abdominal pain/dyspepsia

90 (45%)

69 (23%)

< 0.0001

   Heartburn

58 (29%)

30 (10%)

< 0.0001

   Dysphagia

23 (12%)

26 (9%)

0.2676

   Anemia

23 (12%)

25 (8%)

0.2112

   Variceal screening

1 (0.5%)

24 (8%)

< 0.0001

  Gastric erythema

185 (93%)

137 (45%)

< 0.0001

   Hiatal hernia

45 (22%)

42 (14%)

0.0108

  Peptic ulcer

26 (13%)

31 (10%)

0.3211

  Erosions

0 (0%)

19 (6%)

0.0003

   White plaques

0 (0%)

12 (4%)

0.0046

  Gastritis

172 (86%)

145 (48%)

< 0.0001

  Esophagitis

29 (15%)

29 (10%)

0.0838

  Helicobacter pylori

44 (22%)

12 (4%)

< 0.0001

   Duodenitis

24 (12%)

18 (6%)

0.0150

  Gastric polyp

14 (7%)

5 (2%)

0.0019

  Candida esophagitis

0 (0%)

8 (3%)

0.0179

Indications/presenting symptoms

Endoscopic findings

Histological findings

µL or higher, and those not taking any HIV-targeted therapy
versus those on HAART. The patients compliant with HAART
were further categorized into one of three groups, based on
the specific HAART regimen they were taking at the time of
endoscopy: backbone of non-nucleoside reverse transcriptase
inhibitors (NNRTIs) versus protease inhibitors (PIs) versus integrase inhibitors (IIs).
Data collected included indications for endoscopy, the endoscopic findings, biopsy results, age, sex, and ethnicity, HIV
status, CD4 count, medications, comorbidities, and social history such as smoking or alcohol use. The different groups of the
study were compared with respect to these parameters. Statistical analyses were performed using Statistical Analysis System
(SAS) version 10.1 and significant level of P = 0.05 was used.

Results
In a total eligible population of 503 patients, 304 were HIVpositive and 199 were HIV-negative patients. In this group, 376
esophagogastroduodenoscopies (EGDs) (of which 126 were for
HIV-positive patients) and 378 colonoscopies (of which 231
were for HIV-positive patients) were performed and analyzed.
Mean ages in the two groups were statistically equivalent (54
and 53 in the HIV and control groups, respectively; P = 0.1768).
The HIV group comprised significantly more males (54% vs.
35%; P = 0.0001), more smokers (29% vs. 11%; P = 0.0001),
more alcohol users (25% vs. 7%; P = 0.0001), and fewer proton
pump inhibitor (PPI) users (19% vs. 29%; P = 0.0115).
Overall, the most common indications for EGD were dys96

pepsia (32%), heartburn (18%), dysphagia (10%), and anemia
(10%). Dyspepsia and heartburn were significantly less common in HIV patients (10% vs. 29%, P < 0.0001 for heartburn).
The most common gross findings on EGD were gastric mucosal erythema (64%), hiatal hernia (17%), peptic ulcer (11%),
and gastric erosions (4%). In HIV patients, gastric erythema
(45% vs. 93%, P < 0.0001) and hiatal hernia (14% vs. 22%, P =
0.0108) were significantly less common, and erosions (6% vs.
0%, P = 0.0003) more common. The most common histological findings from EGD were gastritis (63%), Helicobacter pylori infection (11%), esophagitis (11%), and duodenitis (8%).
In HIV patients, gastritis (48% vs. 86%, P < 0.0001) including
Helicobacter pylori infection (4% vs. 22%, P < 0.0001) were
significantly less common, while Candida esophagitis (3% vs.
0%, P = 0.0179) was more common (Table 1).
Overall, the most common indications for colonoscopy
were screening (46%), bleeding (13%), abdominal pain (7%),
and anemia (7%). Anemia (6% vs. 11%, P = 0.253) and abdominal pain (5% vs. 11%, P < 0.0001) were significantly less
common in HIV. The most common gross findings on colonoscopy were hemorrhoids (49%), polyps (30%), and diverticulosis (19%). The most common histological findings from
colonoscopy were hyperplastic polyps (12%), adenomas (6%),
and mucosal lymphoid aggregates (4%). In HIV, both hyperplastic polyps (20% vs. 9%, P = 0.0005) and mucosal lymphoid aggregates (6% vs. 0%, P = 0.0003) were more common.
Adenomas (10% vs. 14%, P = 0.2008) and other histological
findings were equivalently prevalent between HIV patients
and controls (Table 2).
Among HIV patients, those with CD4 counts less than

Articles © The authors | Journal compilation © Gastroenterol Res and Elmer Press Inc™ | www.gastrores.org

Parvin et al

Gastroenterol Res. 2018;11(2):95-99

Table 2. Colonoscopy Indications, Gross Findings, and Histological Findings
HIV-negative (n = 199)

HIV-positive (n = 304)

P value

  Screening

85 (43%)

145 (48%)

0.2430

  Gastrointestinal bleeding

24 (12%)

42 (14%)

0.5701

   Anemia

22 (11%)

17 (6%)

0.0253

   Abdominal pain

22 (11%)

14 (5%)

< 0.0001

   Hemorrhoids

96 (48%)

148 (49%)

0.6307

  Colonic polyps

58 (29%)

93 (31%)

0.9617

   Diverticulosis

45 (23%)

53 (17%)

0.1099

   None/normal

4 (2%)

17 (6%)

0.0499

  Colorectal cancer

3 (2%)

8 (3%)

0.3969

   None/normal

96 (48%)

118 (39%)

0.0366

   Hyperplastic polyp

17 (9%)

61 (20%)

0.0005

   Tubular adenoma

27 (14%)

30 (10%)

0.2008

   Mucosal lymphoid aggregates

0 (0%)

19 (6%)

0.0003

  Colitis

9 (5%)

10 (3%)

0.4792

Indications/presenting symptoms

Colonoscopy findings

Histological findings

200 cells/µL had lower rates of diverticulosis (7% vs. 21%;
P = 0.0402) and hemorrhoids (31% vs. 52%; P = 0.0107), as
compared with those with CD4 counts greater than 200 cells/
µL. Other gross and histological findings (from either upper or
lower endoscopy) were statistically equivalent between these
two groups. Among HIV patients taking different HAART
regimens, there were no significant differences in endoscopic
findings, except that the prevalence of peptic ulcers was significantly higher in those taking IIs (15%) versus those taking
NNRTIs (8%) or PIs (7%) (P = 0.0495).

Discussion
HIV/AIDS is a multisystemic disorder that affects virtually
every organ of the body. The GI system is one of the most
common organ-systems to be affected by HIV/AIDS, producing a wide variety of symptomatic complaints. Given that
HIV/AIDS is an immunological disorder, infectious etiologies,
both opportunistic and non-opportunistic, are among the most
important factors in HIV symptomatology. With the advent
of HAART, particularly the newer regimens of antiretroviral
therapy, the incidence and prevalence of various GI infections
in HIV have changed dramatically.
In our study, mucosal erythema of the upper GI tract and
histologically defined esophagitis, gastritis, or duodenitis from
various causes were among the most common findings. Candida esophagitis is the most common esophageal disorder observed in HIV patients [2], with a prevalence of 43-53% in
the pre-HAART era, and 17-24% since the introduction of
HAART [2]. In our study, the incidence of Candida esophagitis
was higher in HIV-positive patients than that of HIV-negative

patients. Our results were similar to many prior studies, where
the incidence of Candida esophagitis in HIV-positive patients
was significantly higher than that of HIV-negative patients [2].
Numerous studies further demonstrate that the prevalence of
Candida is higher in HIV-positive patients with CD4+ count <
200 cells/µL than those with CD4+ count > 200 cells/µL, and
higher in those with a greater HIV viral load [2, 3]. Our study
revealed a 3.0% prevalence of Candida esophagitis, lower than
previously reported since the introduction of HAART new
regimens. Our results indicate that the effectiveness of the new
HAART regimens.
Cytomegalovirus (CMV), herpes simplex virus (HSV),
and Kaposi’s sarcoma are other important etiologies of esophagitis in HIV patients. CMV esophagitis is characterized
by symptoms of odynophagia, dysphagia and endoscopic findings of multiple, well-demarcated vertical/horizontal linear
shallow ulcers, most commonly between the mid-third and
lower-third areas of the esophagus [4]. HSV is the least common of the infectious agents that cause esophagitis in HIVinfected patients. The shallow erosive ulcers are similar to
erosive reflux esophagitis and have a wider distribution pattern
than CMV [5]. Kaposi's sarcoma is rarely found in the esophagus, and presents as dysphagia rather than odynophagia [5]. It
appears as submucosal ulcerations or as linitis plastica in the
stomach [6]. While Kaposi’s sarcoma lesions in the latter parts
of the upper GI tract are generally asymptomatic, it has been
reported to cause acute hemorrhage [6, 7]. Our study did not
document any cases of CMV/HSV infection or cases of Kaposi’s sarcoma or lymphoma, likely due to a relatively small
sample size and higher CD4 count than that is usually found in
patients with these disease entities.
As in the general population, infection with Helicobacter
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pylori is an important finding in HIV patients. In our study,
both Helicobacter pylori and gastroduodenitis of any etiology
were less common in HIV patients, as compared with control subjects. These findings are congruent with prior studies,
where the prevalence of Helicobacter pylori was less in HIVpositive patients as compared with HIV-negative patients, and
in those with a CD4 count of < 200 cells/µL than those with
a CD4 count of > 200 cells/µL [2, 8-11]. These results could
be the consequence of HIV-positive patients receiving multiple antibiotics therapeutically or prophylactically for typical
or opportunistic infections, commonly having received erythromycin, amoxicillin or broad spectrum antibiotics [11]. An
impairment of Helicobacter pylori colonization might also be
due to progressive atrophic involution of the gastric mucosa
with secondary hypochlorhydria, representing an unfavorable
environment [8-10]. Another possibility is that for Helicobacter pylori to persist in a gastric environment, it requires an
intact mucosal cellular immunity and inflammatory response
leading to gastritis, which is a response that has been reported
to be decreased in CD4+ T-cell-deficient individuals [12].
In our study, the most common findings on lower endoscopy were hemorrhoids, polyps, and diverticulosis with the
relative prevalence of these findings statistically equivalent between HIV-positive and HIV-negative patients. On histology,
however, hyperplastic polyps and mucosal lymphoid aggregates on biopsy samples were more common in HIV-positive
patients. Kasapovic et al investigated rates of mucosal abnormalities detected by screening colonoscopy in 96 HIV-infected
patients over the age of 50 in Germany, and found that the adenoma detection rate during colorectal cancer (CRC) screening colonoscopy in HIV-positive patients was higher than that
seen in the general population in the country [13]. Their data
showed that adenomas were detected in 26% of all screened
HIV-positive patients, while published data predict adenoma
detection rates of 12-20% in the general population [14]. Studies in the United States such as from Bini et al showed that,
compared with control subjects, HIV-positive patients were
significantly less likely to have hyperplastic polyps and were
significantly more likely to have adenomas 6 - 9 mm in diameter [15]. Advanced neoplastic lesions and colorectal adenocarcinomas were more common in HIV-positive patients,
although these differences did not reach statistical significance
[15]. In our study, the relative prevalence of colonic polyps
on endoscopy was statistically equivalent between our HIVpositive and HIV-negative patients, possibly because the statistical power may not have been strong enough to detect a difference. Alternatively, the study population in our study may
be different as we included patients undergoing colonoscopy
for screening (48%) as well as for other indications such as GI
symptoms (52%).
One hospital-based cross-sectional study in Cameroon
was undertaken in order to determine the prevalence and determinants of anorectal pathology in 390 HIV-infected patients
who visited a hospital HIV treatment center [16]. The median
duration since HIV diagnosis was 3 years and the median CD4
count was 411 cells/µL [16]. The prevalence of anorectal pathology was 22.8% [16]. Hemorrhoids and proctitis were the
most common lesions found; each was discovered in 10% respectively [16]. In our study, hemorrhoids were the most com98
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mon findings on colonoscopy in both the HIV-positive cohort
and the HIV-negative cohort.
After the widespread use of HAART, several studies
showed changes in the incidence of AIDS-defining and nonAIDS-defining malignancies among HIV/AIDS patients. One
systematic review of 21 observational studies, involving more
than 600,000 HIV-positive individuals and 10,891 new cases
of malignancies, evaluated the incidence of cancers before and
after the introduction of HAART [17]. After introduction of
HAART, the incidence of AIDS-defining cancers (e.g., Kaposi’s sarcoma and non-Hodgkin’s lymphoma) decreased significantly, as HAART decreased the patient’s total HIV burden,
maintained immune system function, and prevented opportunistic infections that previously led to death [17]. The incidence
of several non-AIDS-defining cancers increased after the early
use of HAART, likely due to the increased survival made possible by the new antiretroviral drugs [17]. In our study, the
rates of colorectal cancer were statistically equivalent between
the HIV-positive and HIV-negative groups. Interestingly,
studies that have compared pre- and post-HAART eras have
demonstrated, on a consistent basis, an alarming increase in
the incidence of invasive anal cancer during the HAART era
[18]. The reasons for this development are likely multifactorial. There are several theories but further research is needed to
explain this finding.
Our study findings yielded low rates of colitis or specific
colonic infectious agents, possibly due to small sample sizes.
However, lower GI infections certainly are important entities
in GI disorders in the setting of HIV. Since the introduction
of HAART, the incidence of opportunistic infections has decreased significantly, but has not disappeared. In fact, in large
inner-city hospitals, where there are often more HIV-infected
patients, who are either unaware of their HIV status or noncompliant with their HAART regimens, GI symptoms and
corresponding endoscopic findings and biopsy results are not
uncommon [19]. There is a broad spectrum of pathogens and
opportunistic infections that affect the lower GI tract in HIV/
AIDS. These include bacterial infections (Listeria, Salmonella, Shigella, Mycobacterium avium complex, and spirochetes),
viral infections (CMV, adenovirus, and herpes simplex), fungal infections (Candida, Cryptococcus, Histoplasma, and microsporidia), and parasitic infections (Giardia, Isospora, and
cryptosporidium) [19]. In our study, the etiology of colitis has
not been further subclassified.
Although the frequency of opportunistic infections in
HIV-positive individuals with CD4 counts greater than 200
was low, performing colonoscopy was still useful, especially
to diagnose CMV infection [20]. Indeed, although the use of
HAART has led to a decreased incidence of opportunistic infections, the physician should not abandon the possibility that
the GI symptoms in HIV-infected patients on HAART may be
due to an opportunistic infection, even when the CD4 count is
high and the viral load is low [21].
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